计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175563-100μg |
100μg |
现货 ![]() |
| |
| Ab175563-1mg |
1mg |
现货 ![]() |
| |
| Ab175563-5mg |
5mg |
现货 ![]() |
| |
| Ab175563-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Indusatumab vedotin (anti-GUCY2C), 鸟苷酸环化酶-C 抗体 |
|---|---|
| 别名 | 维汀-英度妥单抗 | Indusatumab vedotin(抗 GUCY2C) |
| 英文别名 | GC-C antibody | Guanylyl cyclase C antibody | GUC2C antibody | GUC2C_HUMAN antibody | GUCY2C antibody | Heat stable enterotoxin receptor antibody | Heat-stable enterotoxin receptor antibody | hSTAR antibody | Intestinal guanylate cyclase antibody | STA re |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥90%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | GUCY2C |
| 种属反应性 | 人(Human) |
| 偶联 | MC-VC-PAB-MMAE |
| 作用类型 | 抑制剂 |
| 作用机制 | 鸟苷酸环化酶-C 抗体 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 145 kDa |
| 纯化方法 | Protein A purified |
| 纯度 | >90% (SDS-PAGE&SEC) |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1514889-12-3 |
| 分子类型 | 抗体偶联药物 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
Indusatumab vedotin (anti-GUCY2C) (Ab175563) - ELISA
Immobilized Recombinant Human GUCY2C protein ,His tag at 2.0 μg/mL can bind Indusatumab vedotin (anti-GUCY2C) (Ab175563) with the EC50 of 5.021 ng/mL.
Indusatumab vedotin (anti-GUCY2C) (Ab175563) - SEC
The purity of Indusatumab vedotin (anti-GUCY2C) (Ab175563) is more than 95% verified by HPLC.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | Ab175563 | |
| 分析证书 | Ab175563 | |
| 分析证书 | Ab175563 | |
| 分析证书 | Ab175563 | |
| 分析证书 | Ab175563 | |
| 分析证书 | Ab175563 |
| 1. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. (2000) Guanylyl cyclases and signaling by cyclic GMP.. Pharmacol Rev, 52 (3): (375-414). [PMID:10977868] |
| 2. Schulz S, Hyslop T, Haaf J, Bonaccorso C, Nielsen K, Witek ME, Birbe R, Palazzo J, Weinberg D, Waldman SA. (2006) A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer.. Clin Cancer Res, 12 (15): (4545-52). [PMID:16899600] |
| 3. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA. (2005) Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.. Hum Pathol, 36 (2): (170-9). [PMID:15754294] |
| 4. Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, Van Laethem JL, López CM, Alsina M, Muñoz FL, Bendell J et al.. (2017) Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.. Invest New Drugs, 35 (2): (235-241). [PMID:28188407] |
| 5. Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J et al.. (2017) A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.. Invest New Drugs, 35 (5): (634-641). [PMID:28527133] |
| 6. Carrithers SL, Barber MT, Biswas S, Parkinson SJ, Park PK, Goldstein SD, Waldman SA. (1996) Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues.. Proc Natl Acad Sci USA, 93 (25): (14827-32). [PMID:8962140] |